3SBio Inc.



Quote for 3SBio Inc.

Last Trade:
-
Change:
--
Symbol:
SSRX
Status:
-
Listed In:
NASDAQ
P/E:
-
EPS:
-
Market cap:
-
Beta:
-
Open:
-
Prev Close:
-
Capital:
-
Volume:
-
Average vol:
-
Amount:
-
Day's Range:
-
52 week Range:
-
Update:-
Quote Delayed 15 Min.
Currency in USD Time=EDTSSRX quote

Summary for 3SBio Inc.

3SBio Inc. is a fully integrated biotechnology company focused on research and development, manufacturing and marketing capabilities focusing on bio-pharmaceutical products. The Company's recombinant, or genetically engineered, protein-based products and product candidates are designed to address large markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Its principal products are EPIAO and TPIAO. In addition, it has two legacy products, Intefen and Inleusin, and an in-licensed product, Iron Sucrose Supplement. On November 4, 2010, the Company acquired the worldwide rights, exclusive of Taiwan, of Pegsiticase (or Uricase-PEG 20), from EnzymeRx, LLC (EnzymeRX). In December 2010, it acquired 40% interest in Ascentage Pharma Group Corporation, Ltd. In June 2010, it acquired 40% interest in Ascentage Shanghai Pharmaceutical Co., Ltd.